To further establish the clinical relevance of TRIM4 as a modulator of TAM sensitivity in breast cancer patients, we next prepared organoids derived from ER‐α‐positive patients which were then infected using TRIM4‐expressing or control retroviruses and plated in organoid culture media and Matrigel. This evidence concerns the gene ESR1 and breast cancer.